2nd European Oncology and Immuno-Oncology
Drug Discovery Symposium, Basel
How to Overcome Preclinical Development Hurdles
and Accelerate Transition through Clinical Trials
Date: Tuesday 22nd October, 2019 9:00-17:00
Venue: Hotel Stücki, Badenstrasse 1, 4057 Basel
Registration is Full!
Due to overwhelming demand, this event is at full capacity.
Join the Wait List!
Registrants will typically notify us prior to the event if they are no longer able to attend. We will notify you as soon as possible when a seat becomes availabile.
Please complete the form to join the wait list. Your mobile number will allow us to contact you quickly via text message to confirm your seat.
Learn from experts about their current therapeutic approach to today’s oncology challenges. Gain insight on how to further support your oncology and immuno-oncology drug development programs, from preclinical and translational studies, to research in the clinic, by attending the Champions Oncology drug discovery symposium.
RESERVE YOUR SPOT ON THE WAITING LIST NOW – FREE REGISTRATION
Who Should Attend
R&D, discovery, preclinical and translational teams from pharma, biotech, and academia
Presentations and Speakers
Keynote Speaker: Dr. Bruno Gomes
HEAD OF BIOMARKERS ONCOLOGY, ROCHE
Title: Challenges and opportunities for biomarkers in early clinical development
Dr. Andreas Katopodis
CEO, ANAVEON AG
Title: Re-Focusing IL-2 to fuel anti-cancer immunity
Dr. Raj Lehal
CSO, CELLESTIA BIOTECH AG
Title: Discovery and development of a first-in-class protein-protein interaction inhibitor targeting the NOTCH pathway
Dr. Marina Udier
Title: Changing the game with best-in-class neoantigen cancer vaccine
Dr. Henning Lauterbach
EXECUTIVE DIRECTOR – PRECLINICAL R&D, HOOKIPA PHARMA INC.
Title: Live attenuated arenavirus-based vectors for active cancer immunotherapy
Dr. Jayesh Majithiya, MPharm, PhD
SENIOR SCIENTIST TRANSLATIONAL BIOLOGY, CRESCENDO BIOLOGICS LTD
Title: CB307, A novel T-cell agonist humabody therapeutic for PSMA-positive tumours
Dr. Zaki Sellam
Title: T cell therapies – From challenges to promising perspectives Insights to ATICure new generation of T cell therapies
Dr. Patrick Nef
CEO, TRANSCURE BIOSERVICES
Title: Transient human cytokine expression for advanced and physiological full human immune system reconstitution in hu-NCG for CDX and PDX’s preclinical in vivo pharmacology studies
Dr. Amy Wesa
DIRECTOR OF IMMUNO-ONCOLOGY RESEARCH, CHAMPIONS ONCOLOGY, INC.